Baldini V, Mastropasqua M, Francucci CM, D’Erasmo E (2005) Cardiovascular disease and osteoporosis. J Endocrinol Invest 28:69–72

CAS  Google Scholar 

von der Recke P, Hansen MA, Hassager C (1999) The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 106:273–278. https://doi.org/10.1016/s0002-9343(99)00028-5

Article  Google Scholar 

Tankó LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR (2005) Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 20:1912–1920. https://doi.org/10.1359/JBMR.050711

Article  Google Scholar 

Makovey J, Chen JS, Hayward C, Williams FM, Sambrook PN (2009) Association between serum cholesterol and bone mineral density. Bone 44:208–213. https://doi.org/10.1016/j.bone.2008.09.020

Article  CAS  Google Scholar 

Ghorabi S, Shab-Bidar S, Sadeghi O, Nasiri M, Khatibi SR, Djafariar K (2019) Lipid profils of bone fracture: a systematic review and meta-analysis of obstervational studies. Endocr Res 44:168–184. https://doi.org/10.1080/07435800.2019.1625057

Article  CAS  Google Scholar 

Edwards CJ, Hart DJ, Spector TD (2000) Oral statins and increased bone-mineral density in postmenopausal women. Lancet 355:2218–2219. https://doi.org/10.1016/s0140-6736(00)02408-9

Article  CAS  Google Scholar 

Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA reductase Inhibitors and the risk of fractures. JAMA 283:3205–3210. https://doi.org/10.1001/jama.283.24.3205

Article  CAS  Google Scholar 

Mandal CC (2015) High cholesterol deteriorates bone health: new insights into molecular mechanisms. Front Endocrinol 6:165. https://doi.org/10.3389/fendo.2015.00165

Article  Google Scholar 

Domini E, Brozek W, Peter RS, Fromm E, Ulmer H, Killian R, Concin H, Nagel G (2020) Metabolic factors and hip fracture risk in a large Austrian cohort study. Bone Rep 12:100244

Article  Google Scholar 

Wang Y, Dai J, Zhong N, Hu C, Lu S, Chai Y (2018) Association between serum cholesterol level and osteoporotic fracture. Front Endocr (Lausanne) 9:30

Article  Google Scholar 

Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96:133–138. https://doi.org/10.1073/pnas.96.1.133

Article  CAS  Google Scholar 

van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S (1999) Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255:491–494. https://doi.org/10.1006/bbrc.1999.0224

Article  Google Scholar 

Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032–1045. https://doi.org/10.4065/83.9.1032

Article  CAS  Google Scholar 

Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E (2000) Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 15:599–604. https://doi.org/10.1359/jbmr.2000.15.3.599

Article  CAS  Google Scholar 

Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, Matsumoto K, Palkowitz AD, Sato M, Termine JD, Winter MA, Yang NN, Dodge JA (1997) Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 94:14105–14110. https://doi.org/10.1073/pnas.94.25.14105

Article  CAS  Google Scholar 

Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK, Raloxifene Use for The Heart (RUTH) Trial Investigators (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137. https://doi.org/10.1056/NEJMoa062462

Article  CAS  Google Scholar 

Uemura Y, Tanaka S, Miyazaki T, Tsukiyama M, Sone T, Taguchi A, Soen S, Mori S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M, Adequate Treatment of Osteoporosis (A-TOP) research group (2019) Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04. J Bone Miner Metab 37:491–495. https://doi.org/10.1007/s00774-018-0942-z

Article  CAS  Google Scholar 

Uemura Y, Sone T, Tanaka S, Miyazaki T, Tsukiyama M, Taguchi A, Soen S, Mori S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M (2020) Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04. Curr Med Res Opin 36:1847–1859. https://doi.org/10.1080/03007995.2020.1816537

Article  CAS  Google Scholar 

Orimo H (2007) The Japanese guidelines for the prevention and treatment of osteoporosis. Osteoporos Jpn 15:351–355

Google Scholar 

Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148. https://doi.org/10.1002/jbmr.5650080915

Article  CAS  Google Scholar 

Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K (2018) Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscl Thromb 25(9):846–984. https://doi.org/10.5551/jat.GL2017

Article  Google Scholar 

Johnston CC Jr, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper MW, Harper KD, Heath H, Gennari C, Christiansen C, Arnaud CD, Delmas PD (2000) Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160:3444–3450. https://doi.org/10.1001/archinte.160.22.3444

Article  CAS  Google Scholar 

Guney E, Kisakol G, Ozgen AG, Yilmaz C, Kabalak T (2008) Effects of bisphosphonates on lipid metabolism. Neuro Endocrinol Lett 29:252–255

CAS  Google Scholar 

Parhami F, Jackson SM, Tintut Y, Le V, Balucan JP, Territo M, Demer LL (1999) Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells. J Bone Miner Res 14:2067–2078. https://doi.org/10.1359/jbmr.1999.14.12.2067

Article  CAS  Google Scholar 

Jeong IK, Cho SW, Kim SW, Choi HJ, Park KS, Kim SY, Lee HK, Cho SH, Oh BH, Shin CS (2010) Lipid profiles and bone mineral density in pre- and postmenopausal women in Korea. Calcif Tissue Int 87:507–512. https://doi.org/10.1007/s00223-010-9427-3

Article  CAS  Google Scholar 

Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R (2010) Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 362:686–696. https://doi.org/10.1056/NEJMoa0808692

Article  CAS  Google Scholar 

Insull W, Davidson MH, Kulkarni PM, Siddhanti S, Ciaccia AV, Keech CA (2005) Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. Metabolism 54:939–946. https://doi.org/10.1016/j.metabol.2005.02.010

Article  CAS  Google Scholar